MAB13415
Anti-MMP-9 Antibody, clone GE-213
clone GE-213, Chemicon®, from mouse
Synonym(s):
Gelatinase B, 92 kDa Type IV Collagenase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
GE-213, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... MMP9(4318)
Related Categories
Specificity
Under non-reducing conditions, it recognizes proteins of 92 kDa and 86 kDa which are identified as pro (latent) and active forms of matrix metalloproteinase-9 (MMP-9; also known as 92 kDa and collagenase IV or gelatinase B) of human MMP-9. MAB13415 reacts with the complex (~200 kDa) of MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1; Nikkari et al., 1996). It shows no cross-reaction with pro and active forms of MMP-2 (Nikkari et al., 1996). Clone GE-213 also shows very low reactivity to mouse MMP-9 proteins by western blot, but at high enough antibody and antigen concentrations some detection is possible. Mouse immunhistochemistry is untested. Cellular Localization: Peripheral cytoplasmic.
Immunogen
Purified human gelatinase B.
Application
Anti-MMP-9 Antibody, clone GE-213 is an antibody against MMP-9 for use in IP, WB & IH.
Research Category
Cell Structure
Cell Structure
Research Sub Category
MMPs & TIMPs
MMPs & TIMPs
Western Blotting (non-reducing; Nikkari et al., 1996) (Use Ab at 1μg/mL for 2hrs at RT)
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Linkage
Replaces: 04-1150
Physical form
Format: Purified
Purified from ascites fluid by Protein G chromatography. Liquid in 10 mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.
Storage and Stability
Maintain at 2-8°C in undiluted aliquots for up to 12 months from date of receipt.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
Analysis Note
Control
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Manufactured by Daiichi Fine Chemical Co., Ltd
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy, R; Louis, G; Loughlin, KR; Wiederschain, D; Kilroy, SM; Lamb, CC; Zurakowski, D; Moses, MA
Clinical cancer research : an official journal of the American Association for Cancer Research null
Jenny Paupert et al.
Cell cycle (Georgetown, Tex.), 7(8), 1047-1053 (2008-04-17)
The metalloprotease 9 (MMP-9), a known mediator of tumour invasion, is secreted as a 92 kDa pro-form but a non-secreted variant of 85 Kda has been described. The importance of this variant pro-form in tumor progression remains poorly defined. We
Jerzy Krupinski et al.
Vascular health and risk management, 3(4), 405-412 (2007-11-01)
Advanced atherogenesis is characterized by the presence of markers of enhanced prothrombotic capacity, attenuated fibrinolysis, and by clinical conditions associated with defective coagulation. Diabetes may be associated with enhanced lesion instability and atherosclerotic plaque rupture. Plaques obtained from 206 patients
Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids.
Ferdinando Mannello et al.
Clinical chemistry, 49(9), 1546-1550 (2003-08-21)
Themis R Kyriakides et al.
Matrix biology : journal of the International Society for Matrix Biology, 28(2), 65-73 (2009-04-22)
Matrix metalloproteinase- (MMP-9) is involved in processes that occur during cutaneous wound healing such as inflammation, matrix remodeling, and epithelialization, To investigate its role in healing, full thickness skin wounds were made in the dorsal region of MMP-9-null and control
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service